XML 35 R24.htm IDEA: XBRL DOCUMENT v3.25.3
SEGMENT AND ENTERPRISE-WIDE INFORMATION
 6 Months Ended
Sep. 27, 2025
Segment Reporting [Abstract]  
SEGMENT AND ENTERPRISE-WIDE INFORMATION
17. SEGMENT AND ENTERPRISE-WIDE INFORMATION
The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker (“CODM”), identified as the Company’s Chief Executive Officer.
The Company’s reportable and operating segments are as follows:
•Plasma
•Blood Center
•Hospital
The CODM measures and evaluates the operating segments based on operating income for purposes of assessing business performance and allocating resources. Certain corporate expenses and amounts considered to be non-recurring or non-operational are excluded from segment operating income. These items include acquisition, integration and divestiture related costs, amortization of acquired assets, restructuring costs, restructuring related costs, digital transformation costs related to the upgrade of the Company’s enterprise resource planning system, impairments and write downs, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”), unusual or infrequent and material litigation-related charges and gains, losses on dispositions and sale of assets, remeasurement of the contingent consideration liability and unusual or infrequent gains such as on repurchases of convertible notes or divestitures. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. During the fourth quarter of fiscal 2025, the CODM began reviewing financial information including allocations of certain corporate costs including global functional support and overhead costs determined to benefit the segments. The prior period segment disclosures have been recast to reflect the new presentation.
The Company does not track its assets by segment, and as a result it is not practical to show assets or depreciation by segment. Consequently, the Company’s CODM does not review assets by segment when assessing business performance and allocating resources.
Selected information by reportable segment is presented below:
Three Months EndedSix Months Ended
September 27, 2025September 28, 2024September 27, 2025September 28, 2024
(Dollars in Thousands)
Net revenues:
Plasma$125,364 $138,561 $255,261 $274,471 
Blood Center56,454 68,528 108,293 134,773 
Hospital145,497 138,422 285,155 272,439 
Total net revenues$327,315 $345,511 $648,709 $681,683 
Significant segment expenses and operating performance:
Plasma
Cost of goods sold$53,019 $65,726 $102,936 $131,064 
Selling, general and administrative24,761 25,262 50,959 50,392 
Research and development4,993 3,147 10,490 6,866 
Plasma operating income$42,591 $44,426 $90,876 $86,149 
Blood Center
Cost of goods sold$26,948 $36,311 $52,896 $72,491 
Selling, general and administrative13,504 15,202 27,186 30,804 
Research and development1,177 1,213 2,496 2,897 
Blood Center operating income$14,825 $15,802 $25,715 $28,581 
Hospital
Cost of goods sold$49,318 $47,706 $99,534 $96,391 
Selling, general and administrative57,966 58,806 120,289 119,996 
Research and development8,352 8,633 17,094 16,256 
Hospital operating income$29,861 $23,277 $48,238 $39,796 
Corporate and unallocated expenses
Amortization of acquired intangible assets$(13,237)$(16,003)$(27,065)$(33,713)
Acquisition, integration and divestiture related costs(1,520)(882)(4,202)(13,205)
Restructuring and restructuring related costs(258)(6,363)(1,582)(13,503)
Digital transformation costs(5,054)(4,858)(10,409)(11,203)
Other(1)
(8,717)(3,702)(9,208)8,551 
Operating income58,491 51,697 112,363 91,453 
Interest and other expense, net(7,206)(6,993)(15,909)(36)
Income before provision for income taxes$51,285 $44,704 $96,454 $91,417 
__________
(1)    Comprised of litigation-related charges, impairment of intangible assets, and remeasurement of contingent consideration for the three and six months ended September 27, 2025. Comprised of MDR and IVDR costs, litigation-related charges, gains on sale of property, plant and equipment, and impairment of intangible assets for the three and six months ended September 28, 2024.
Net revenues by business unit are as follows:
 Three Months EndedSix Months Ended
September 27, 2025September 28, 2024September 27, 2025September 28, 2024
(Dollars in Thousands)
Plasma
Plasma net revenues$125,364 $138,561 $255,261 $274,471 
Blood Center
Apheresis56,065 54,332 107,887 103,426 
Whole Blood389 14,196 406 31,347 
Blood Center net revenues56,454 68,528 108,293 134,773 
Hospital
Interventional Technologies59,073 61,923 117,556 124,967 
Blood Management Technologies86,424 76,499 167,599 147,472 
Hospital net revenues145,497 138,422 285,155 272,439 
Total net revenues$327,315 $345,511 $648,709 $681,683 
Depreciation and amortization, excluding impairment charges, by business unit are as follows:
Three Months EndedSix Months Ended
September 27, 2025September 28, 2024September 27, 2025September 28, 2024
(Dollars in Thousands)
Plasma$12,033 $12,032 $24,186 $23,948 
Blood Center1,849 2,737 3,608 6,190 
Hospital14,373 14,448 29,219 28,215 
Total depreciation and amortization (excluding impairment charges)$28,255 $29,217 $57,013 $58,353 
Long-lived assets, comprised of property, plant and equipment, by business unit are as follows:
September 27, 2025March 29, 2025
(Dollars in Thousands)
Plasma$204,258 $189,833 
Blood Center39,455 40,337 
Hospital55,304 53,882 
Total long-lived assets$299,017 $284,052 
Long-lived assets, comprised of property, plant and equipment, by operating regions are as follows:
September 27, 2025March 29, 2025
(Dollars in Thousands)
United States$223,664 $217,212 
Japan1,195 1,250 
Europe25,292 20,024 
Rest of Asia30,940 28,705 
Other17,926 16,861 
Total long-lived assets$299,017 $284,052 
Net revenues by operating regions are as follows:
Three Months EndedSix Months Ended
September 27, 2025September 28, 2024September 27, 2025September 28, 2024
(Dollars in Thousands)
United States$240,089 $256,061 $482,493 $504,963 
Japan18,011 16,424 31,659 30,129 
Europe42,965 41,991 83,847 89,216 
Rest of Asia22,567 25,768 44,215 45,551 
Other3,683 5,267 6,495 11,824 
Total net revenues$327,315 $345,511 $648,709 $681,683